



Human Anti-Certolizumab pegol monoclonal antibody, clone AbD34201ia (CABT-ZB1166)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Certolizumab pegol
Target	Certolizumab pegol
Immunogen	Certolizumab pegol
Isotype	IgG1, κ
Source/Host	Human
Species Reactivity	N/A
Clone	AbD34201ia
Affinity Constant	The monovalent intrinsic affinity of AbD34201ia was measured as $K_D = 1$ nM by real time, label free molecular interaction analysis on immobilized certolizumab pegol.
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in ADA bridging ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	Lot specific
Size	100 µg

Buffer	PBS
Preservative	0.01% Thiomersal
Storage	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Ship	Wet ice

BACKGROUND

Introduction	Certolizumab pegol (Cimzia) is a humanized Fab fragment antibody (50 kDa), covalently bound to two polyethylene glycol (PEG) chains (PEG2MAL, 40 kDa) via a thioether linkage; total molecular weight 90.8 kDa. PEG helps to delay the metabolism and elimination of the drug. The removal of the Fc region increases the half-life of the drug and prevents complement fixation and antibody-mediated cytotoxicity. The drug is approved for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It binds to free and membrane-bound human TNF α and neutralizes its activity by inhibiting the binding of TNF α to human p55 and p75 TNF receptors.
Keywords	Certolizumab pegol, Cimzia